Company Filing History:
Years Active: 2013
Title: Thomas Kidd: Innovator in the p21 Pathway Modulation
Introduction
Thomas Kidd is a notable inventor based in Truckee, CA (US). He has made significant contributions to the field of biotechnology, particularly in understanding the p21 pathway and its implications for various disorders.
Latest Patents
Kidd holds a patent titled "RORS as modifiers of the p21 pathway and methods of use." This patent identifies human ROR genes as modulators of the p21 pathway, highlighting their potential as therapeutic targets for disorders associated with defective p21 function. The patent also provides methods for identifying modulators of p21, which include screening for agents that can modulate the activity of ROR.
Career Highlights
Thomas Kidd is currently associated with Exelixis, Inc., a company known for its focus on innovative cancer therapies. His work at Exelixis has allowed him to explore the therapeutic potential of ROR genes in greater depth.
Collaborations
Kidd has collaborated with notable colleagues, including Helen Louise Francis-Lang and Lori Friedman. Their combined expertise has contributed to advancements in the understanding of the p21 pathway.
Conclusion
Thomas Kidd's innovative work in the modulation of the p21 pathway represents a significant advancement in therapeutic strategies for related disorders. His contributions continue to influence the field of biotechnology and cancer research.